C4 Therapeutics (CCCC) Corporate presentation summary

Vision and strategy

• Aims to become a fully integrated biopharmaceutical company focused on best- and first-in-class degraders targeting validated pathways and large market opportunities.

• Pipeline includes clinical oncology and a new discovery strategy in inflammation, neuroinflammation, and neurodegeneration (INN).

• Cash runway expected through end of 2028, supporting execution beyond key value inflection points.

Clinical pipeline and milestones

• Cemsidomide, a next-generation IKZF1/3 degrader, is advancing in multiple myeloma (MM) with Phase 2 and Phase 1b trials underway.

• Phase 2 MOMENTUM trial in 4L+ MM is enrolling, with completion expected in Q1 2027 and initial ORR data in 2H 2027.

• Phase 1b trial combines cemsidomide with elranatamab, targeting deeper responses and MRD negativity; data from all cohorts expected mid-2027.

• Three strategic development paths for cemsidomide: late-line, novel combinations, and IMID replacement across MM lines.

Clinical data and differentiation

• Phase 1 cemsidomide + dexamethasone showed deep, durable responses and a well-tolerated safety profile in heavily pre-treated RRMM patients.

• ORR was consistent across key subgroups, with manageable neutropenia and minimal dose reductions or discontinuations.

• Cemsidomide’s pharmacology supports a convenient 14/14 dosing schedule and is suitable for patients with renal impairment.